HLS Therapeutics Inc.

HLS

CA40390B1094

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 20:59:59 28/06/2024 BST			5-day change	1st Jan Change
3.35 ^CAD	+0.75%		-2.47%	-15.19%

06-07	Transcript : HLS Therapeutics Inc. - Shareholder/Analyst Call
05-28	HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study	MT

Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 9, 2023.

May 09, 2024 at 12:12 pm

From January 1, 2024 to March 31, 2024, the company has repurchased 93,707 shares, representing 0.29% for CAD 0.28 million. With this, the company has completed the repurchase of 93,707 shares, representing 0.29% for CAD 0.28 million under the buyback announced on November 9, 2023.

Latest news about HLS Therapeutics Inc.

Transcript : HLS Therapeutics Inc. - Shareholder/Analyst Call	06-07
HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study	05-28	MT
HLS Therapeutics Inc. Announces New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment	05-28	CI
Transcript : HLS Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance	05-09	MT
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 9, 2023.	05-09	CI
HLS Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
HLS Therapeutics Brief: Q1 2024 revenue was US$12.5 million, Adjusted EBITDA was $2.7 million and cash from operations was $0.8 million	05-09	MT
HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024	05-09	CI
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 9, 2023.	04-12	CI
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 10, 2022.	04-12	CI
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA	04-08	CI
Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024	03-14
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update	03-14	MT
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022	03-14	MT
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million	03-14	MT
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024	03-14	CI
HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14	CI
HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan	02-06	MT
HLS Therapeutics Brief: Announcing that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan	02-06	MT
HLS Therapeutics Inc. Announces CFO Changes	12-18	CI
HLS Therapeutics Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson	12-18	MT
HLS Therapeutics Brief: Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson	12-18	MT
HLS Therapeutics Brief: Adds Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with Placebo	11-14	MT

Chart HLS Therapeutics Inc.

Duration

Period

More charts

Company Profile

HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for HLS Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.448 USD

Average target price

3.885 USD

Spread / Average Target

+58.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
HLS THERAPEUTICS INC.	-15.19%	77.82M
CARDINAL HEALTH, INC.	-2.46%	23.95B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+14.23%	8.7B
SINOPHARM GROUP CO. LTD.	+1.47%	8.29B
HUADONG MEDICINE CO., LTD	-32.92%	6.7B
H. LUNDBECK A/S	+18.62%	5.38B
GALENICA AG	+1.10%	4.08B
EBOS GROUP LIMITED	-9.24%	3.79B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-10.20%	3.3B
MEDIPAL HOLDINGS CORPORATION	+7.11%	3.19B

Pharmaceuticals Wholesale

HLS Therapeutics Inc.

Equities

HLS

CA40390B1094

Pharmaceuticals

Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 9, 2023.

EPS Revisions